VILLA, MATTEO

VILLA, MATTEO  

DIPARTIMENTO DI MEDICINA E CHIRURGIA (SCHOOL OF MEDICINE AND SURGERY)  

Mostra records
Risultati 1 - 13 di 13 (tempo di esecuzione: 0.025 secondi).
Titolo Tipologia Data di pubblicazione Autori File
A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib 01 - Articolo su rivista 2019 Sharma G. G.Cortinovis D.Villa M.Cordani N.Bidoli P.Pagni F.Piazza R.Gambacorti-Passerini C.Mologni L. +
Synergistic drug combinations preventdrug resistance in anaplastic large cell lymphomapreclinical models 02 - Intervento a convegno 2021 Villa, MMauri, MMagistroni, VCeccon, MRedaelli, SCrespiatico, IFontana, DMastini, CPiazza, RGambacorti Passerini, CMologni, L +
Synergistic drug combinations prevent resistance in ALK+ anaplastic large cell lymphoma 01 - Articolo su rivista 2021 Sharma, GGVilla, MMauri, MCrespiatico, IFontana, DMastini, CMagistroni, VCeccon, MRedaelli, SMassimino, LPiazza, RGambacorti Passerini, CMologni, L +
New advances in liquid biopsy technologies for anaplastic lymphoma kinase (Alk)—positive cancer 01 - Articolo su rivista 2021 Villa M.Sharma G. G.Manfroni C.Cortinovis D.Mologni L.
Novel ALK mutations in EML4::ALK+ NSCLC resistant to TKIs identified by liquid biopsy 02 - Intervento a convegno 2022 Villa, MMalighetti, FArosio, GManfroni, CFontana, DCordani, NMeneveri, RZambon, APiazza, RPagni, FCortinovis, DMologni, L +
Evolutionary signatures of human cancers revealed via genomic analysis of over 35,000 patients 01 - Articolo su rivista 2023 Fontana, DCrespiatico, ICrippa, VMalighetti, FVilla, MAngaroni, FAroldi, AAntoniotti, MCaravagna, GPiazza, RGraudenzi, AMologni, LRamazzotti, D +
DNA Damage Response (DDR) Is Associated With Treatment-free Remission in Chronic Myeloid Leukemia Patients 01 - Articolo su rivista 2023 Malighetti, FedericaMauri, MarioVilla, MatteoManghisi, BeatriceInzoli, ElenaRindone, GiovanniCivettini, IvanGuglielmana, VeronicaRamazzotti, DanieleBombelli, SilviaPerego, RobertoPiazza, RoccoMologni, LucaGambacorti-Passerini, Carlo +
Effects of blocking CD24 and CD47 'don't eat me' signals in combination with rituximab in mantle-cell lymphoma and chronic lymphocytic leukaemia 01 - Articolo su rivista 2023 Aroldi, AMauri, MRamazzotti, DVilla, MMalighetti, FCrippa, VCocito, FBorella, CBossi, ESteidl, CScollo, CMologni, LPiazza, RGambacorti Passerini, C +
TWIST1 Upregulation Is a Potential Target for Reversing Resistance to the CDK4/6 Inhibitor in Metastatic Luminal Breast Cancer Cells 01 - Articolo su rivista 2023 Nicoletta CordaniLuca MologniRocco PiazzaPietro TettamantiMario MauriMatteo VillaFederica MalighettiCamillo Di BellaMaria Grazia CerritoGuido CavalettiMarialuisa LavitranoMarina Elena Cazzaniga +
Loss of CDKN2B expression as a potential marker of resistance to CDK4/6 inhibitor in Luminal Breast Cancer cells 02 - Intervento a convegno 2023 Nicoletta CordaniLuca MologniRocco PiazzaCamillo Di BellaMaria Grazia CerritoMatteo VillaGuido CavalettiMarialuisa LavitranoMarina Elena Cazzaniga +
Characterization of cancer subtypes associated with clinical outcomes by multi-omics integrative clustering 01 - Articolo su rivista 2023 Crippa, ValentinaMalighetti, FedericaVilla, MatteoGraudenzi, AlexPiazza, RoccoMologni, LucaRamazzotti, Daniele
Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1 01 - Articolo su rivista 2024 Fontana, DMalighetti, FVilla, MZambon, AGambacorti-Passerini,CMologni, L.
New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients 01 - Articolo su rivista 2024 Villa, MatteoMalighetti, FedericaManfroni, ChiaraFontana, DilettaCordani, NicolettaMeneveri, RaffaellaPiazza, RoccoPagni, FabioCortinovis, DiegoMologni, Luca +